

Balram Chowbay

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9467844/balram-chowbay-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83

papers

4,123

citations

34

h-index

63

g-index

87

ext. papers

4,587

ext. citations

6.5

avg, IF

4.98

L-index

#	Paper	IF	Citations
83	Extracellular vesicle drug occupancy enables real-time monitoring of targeted cancer therapy. <i>Nature Nanotechnology</i> , 2021 , 16, 734-742	28.7	19
82	Pan-Cancer Analysis of Ligand-Receptor Cross-talk in the Tumor Microenvironment. <i>Cancer Research</i> , 2021 , 81, 1802-1812	10.1	14
81	Obesity Alters Endoxifen Plasma Levels in Young Breast Cancer Patients: A Pharmacometric Simulation Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 661-670	6.1	9
80	An intronic FTO variant rs16952570 confers protection against thiopurine-induced myelotoxicities in multiethnic Asian IBD patients. <i>Pharmacogenomics Journal</i> , 2020 , 20, 505-515	3.5	5
79	Colchicine lack of effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): a randomized controlled trial. <i>Osteoarthritis and Cartilage</i> , 2018 , 26, 631-640	6.2	20
78	Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients. <i>Pharmacogenomics</i> , 2018 , 19, 31-43	2.6	25
77	Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib. <i>Scientific Reports</i> , 2017 , 7, 1540	4.9	9
76	EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 529-538	8.9	36
75	Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci. <i>Nature Genetics</i> , 2017 , 49, 993-1004	36.3	72
74	Metronomic chemotherapy: A relook at its basis and rationale. <i>Cancer Letters</i> , 2017 , 388, 328-333	9.9	6
73	Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. <i>Nature Medicine</i> , 2017 , 23, 1167-1175	50.5	109
72	Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen. <i>Frontiers in Pharmacology</i> , 2017 , 8, 582	5.6	37
71	Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review. <i>Drug Metabolism Reviews</i> , 2016 , 48, 502-540	7	15
70	Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukemia & gastrointestinal stromal tumor patients. <i>Pharmacogenomics</i> , 2016 , 17, 1941-1955	2.6	4
69	Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules. <i>PLoS ONE</i> , 2016 , 11, e0154316	3.7	15
68	Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 1142-52	3.8	16
67	Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 1239-1250	6.2	20

66	A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered Des-Aspartate Angiotensin I in Healthy Subjects. <i>Drugs in R and D</i> , 2016 , 16, 317-326	3.4	4
65	Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study. <i>Lancet Oncology</i> , 2016 , 17, 1240-7	21.7	58
64	A common variant mapping to CACNA1A is associated with susceptibility to exfoliation syndrome. <i>Nature Genetics</i> , 2015 , 47, 387-92	36.3	70
63	Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2015 , 88, 289-96	5.9	15
62	Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma. <i>PLoS ONE</i> , 2015 , 10, e0134102	3.7	21
61	Colchicine effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): study protocol for a randomized controlled trial. <i>Trials</i> , 2015 , 16, 200	2.8	15
60	Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>PLoS ONE</i> , 2015 , 10, e0123587	3.7	21
59	Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXR and HNF4) on docetaxel disposition in Chinese nasopharyngeal cancer patients. <i>European Journal of Clinical Pharmacology</i> , 2014 , 70, 155-66	2.8	23
58	Nanoprobe-based genetic testing. <i>Nano Today</i> , 2014 , 9, 166-171	17.9	6
57	8q24 and 17q prostate cancer susceptibility loci in a multiethnic Asian cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1553-60	2.8	18
56	Genetic variations of NR113 and NR2B1 in Asian populations. <i>Drug Metabolism and Pharmacokinetics</i> , 2013 , 28, 169-76	2.2	2
55	Genetic variations of NR2A1 in Asian populations: implications in pharmacogenetics studies. <i>Drug Metabolism and Pharmacokinetics</i> , 2013 , 28, 278-88	2.2	4
54	Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 606-18	3.8	26
53	A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. <i>Nature Medicine</i> , 2012 , 18, 521-8	50.5	433
52	Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 70, 141-50	3.5	7
51	SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. <i>PLoS ONE</i> , 2012 , 7, e51771	3.7	39
50	Pharmacogenomics in Developing Asian Countries. <i>Advances in Microbial Ecology</i> , 2012 , 183-214		
49	Docetaxel pharmacogenetics: The influence of RXR and HNF4 genetic variations on docetaxel disposition in Asian nasopharyngeal carcinoma patients. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2598-2598 ²		

48	Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2011 , 71, 737-50	3.8	94
47	Metabolic profiling of HepG2 cells incubated with S(-) and R(+) enantiomers of anti-coagulating drug warfarin. <i>Metabolomics</i> , 2011 , 7, 353-362	4.7	16
46	The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 1471-8	3.5	60
45	ITRAQ-Coupled 2-D LC-MS/MS Analysis of Differentially Expressed Serum Proteins in Nasopharyngeal Carcinoma Clinical Samples: Potential in Biomarker Discovery. <i>Journal of Medical Imaging and Health Informatics</i> , 2011 , 1, 177-183	1.2	3
44	A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. <i>Clinical Cancer Research</i> , 2011 , 17, 5481-9	12.9	69
43	Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors. <i>Annals of Oncology</i> , 2010 , 21, 382-388	10.3	99
42	Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. <i>Current Drug Metabolism</i> , 2010 , 11, 115-28	3.5	91
41	Secreted protein profile from HepG2 cells incubated by S(-) and R(+) enantiomers of chiral drug warfarin - An analysis in cell-based system and clinical samples. <i>Proteomics - Clinical Applications</i> , 2010 , 4, 808-15	3.1	2
40	A comparative proteomic analysis of HepG2 cells incubated by S(-) and R(+) enantiomers of anti-coagulating drug warfarin. <i>Proteomics</i> , 2010 , 10, 1463-73	4.8	5
39	VKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: transthyretin precursor as a potential biomarker. <i>PLoS ONE</i> , 2010 , 5, e15064	3.7	16
38	VKORC1 diplotype-derived dosing model to explain variability in warfarin dose requirements in Asian patients. <i>Drug Metabolism and Pharmacokinetics</i> , 2009 , 24, 365-75	2.2	12
37	Polymorphism of human cytochrome P450 enzymes and its clinical impact. <i>Drug Metabolism Reviews</i> , 2009 , 41, 89-295	7	579
36	Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. <i>Cancer Science</i> , 2008 , 99, 816-23	6.9	104
35	CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. <i>Cancer Science</i> , 2008 , 99, 2045-54	6.9	32
34	Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients. <i>British Journal of Clinical Pharmacology</i> , 2008 , 65, 260-4	3.8	40
33	Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in Asian women with metastatic breast cancer. <i>Breast</i> , 2008 , 17, 517-22	3.6	4
32	Single nucleotide polymorphisms of the pregnane x receptor gene in Han Chinese and a comparison with other ethnic populations. <i>Pharmacology</i> , 2008 , 81, 350-4	2.3	11
31	PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. <i>Clinical Cancer Research</i> , 2008 , 14, 7116-26	12.9	61

30	Capecitabine-induced oromandibular dystonia: a case report and literature review. <i>Acta Oncologica</i> , 2008 , 47, 1161-5	3.2	7
29	The M351T BCR-ABL Kinase Mutation Is Uncommon in Asian Patients with Imatinib-Resistant Chronic Myeloid Leukemia: Possible Relationship with Imatinib Plasma Levels.. <i>Blood</i> , 2008 , 112, 2122-2122	2.2	1
28	Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. <i>Pharmacogenomics</i> , 2007 , 8, 567-75	2.6	72
27	Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 854, 332-7	3.2	37
26	High performance liquid chromatography with ultraviolet detection for the determination of SYUIQ-5, a novel telomerase inhibitor for cancer therapy: application to an enzyme kinetic study in rat liver microsomes. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 854, 332-7	3.2	2
25	Determination of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase, in human Caco-2 monolayers by high performance liquid chromatography with ultraviolet detection: application to a trans-epithelial transport study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 854, 332-7	3.2	5
24	Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. <i>Cancer Science</i> , 2007 , 98, 1461-7	6.9	108
23	Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations. <i>European Journal of Clinical Pharmacology</i> , 2007 , 63, 555-63	2.8	36
22	Role of P-glycoprotein in limiting the brain penetration of glabridin, an active isoflavan from the root of <i>Glycyrrhiza glabra</i> . <i>Pharmaceutical Research</i> , 2007 , 24, 1668-90	4.5	31
21	A pharmacogenetic study of pregnane X receptor (NR1I2) in Han Chinese. <i>Current Drug Metabolism</i> , 2007 , 8, 778-86	3.5	18
20	An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer. <i>Acta Oncologica</i> , 2007 , 46, 256-8	3.2	4
19	Transport of cryptotanshinone, a major active triterpenoid in <i>Salvia miltiorrhiza</i> Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier. <i>Current Drug Metabolism</i> , 2007 , 8, 365-78	3.5	71
18	Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of <i>Salvia miltiorrhiza</i> Bunge. <i>Current Drug Metabolism</i> , 2007 , 8, 325-40	3.5	69
17	Pharmacogenetics of Oxazaphosphorines and its Clinical Implications. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2007 , 5, 143-156		
16	Clinical Significance of Thiopurine S-Methyltransferase Gene Polymorphisms. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2007 , 5, 103-115		2
15	Tanshinone IIB, a primary active constituent from <i>Salvia miltiorrhiza</i> , exhibits neuro-protective activity in experimentally stroked rats. <i>Neuroscience Letters</i> , 2007 , 417, 261-5	3.3	38
14	EGFR Intron 1 polymorphism in Asian Populations and its correlation with EGFR gene expression and amplification in breast tumor tissues. <i>Cancer Biology and Therapy</i> , 2006 , 5, 1445-9	4.6	13
13	Pharmacogenetics of target genes across the warfarin pharmacological pathway. <i>Clinical Pharmacokinetics</i> , 2006 , 45, 1189-200	6.2	24

12	Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 683-91	1.9	78
11	Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. <i>British Journal of Clinical Pharmacology</i> , 2005 , 59, 415-24	3.8	86
10	Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. <i>British Journal of Clinical Pharmacology</i> , 2005 , 60, 159-71	3.8	105
9	Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma. <i>Cancer</i> , 2005 , 103, 576-81	6.4	42
8	Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models. <i>Cancer Chemotherapy and Pharmacology</i> , 2005 , 56, 569-77	3.5	47
7	An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. <i>Drug Metabolism Reviews</i> , 2005 , 37, 327-78	7	86
6	An Interethnic Comparison of Polymorphisms of the Genes Encoding Drug-Metabolizing Enzymes and Drug Transporters: Experience in Singapore. <i>Drug Metabolism Reviews</i> , 2005 , 37, 327-378	7	36
5	Herbal modulation of P-glycoprotein. <i>Drug Metabolism Reviews</i> , 2004 , 36, 57-104	7	316
4	Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. <i>Pharmacogenetics and Genomics</i> , 2003 , 13, 89-95		225
3	The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents. <i>Oncology Reports</i> , 2003 , 10, 745-51	3.5	11
2	Effect of coenzyme Q10 on the disposition of doxorubicin in rats. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2002 , 27, 185-92	2.7	3
1	Determination of doxorubicin and its metabolites in rat serum and bile by LC: application to preclinical pharmacokinetic studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2002 , 30, 1063-74	2.5	59